Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)

These findings support carboplatin doublet-based chemotherapy in select older patients with advanced NSCLC.